1021 related articles for article (PubMed ID: 15853949)
1. Bet v 1-specific IgA increases during the pollen season but not after a single allergen challenge in children with birch pollen-induced intermittent allergic rhinitis.
Keen C; Johansson S; Reinholdt J; Benson M; Wennergren G
Pediatr Allergy Immunol; 2005 May; 16(3):209-16. PubMed ID: 15853949
[TBL] [Abstract][Full Text] [Related]
2. Low levels of CC16 in nasal fluid of children with birch pollen-induced rhinitis.
Johansson S; Keen C; Ståhl A; Wennergren G; Benson M
Allergy; 2005 May; 60(5):638-42. PubMed ID: 15813809
[TBL] [Abstract][Full Text] [Related]
3. [Humoral mucosal immunity in allergic rhinitis].
Kramer MF; Jordan TR; Pfrogner E; Rasp G
Laryngorhinootologie; 2005 Jul; 84(7):503-10. PubMed ID: 16010632
[TBL] [Abstract][Full Text] [Related]
4. Allergen-reactive antibodies are found in nasal fluids from patients with birch pollen-induced intermittent allergic rhinitis, but not in healthy controls.
Benson M; Reinholdt J; Cardell LO
Allergy; 2003 May; 58(5):386-92. PubMed ID: 12752324
[TBL] [Abstract][Full Text] [Related]
5. No decrease of birch pollen specific IgA and IgG in nasal fluids from cortisone treated patients with intermittent allergic rhinitis.
Benson M; Reinholdt J; Cardell LO
Allergy; 2004 Mar; 59(3):365-7. PubMed ID: 14982528
[No Abstract] [Full Text] [Related]
6. Effect of natural seasonal pollen exposure and repeated nasal allergen provocations on elevation of exhaled nitric oxide.
Bergmann-Hug K; Wirth R; Henseler M; Helbling A; Pichler WJ; Schnyder B
Allergy; 2009 Nov; 64(11):1629-34. PubMed ID: 19627276
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-8 secretion in patients with allergic rhinitis after an allergen challenge: interleukin-8 is not the main chemotactic factor present in nasal lavages.
Gosset P; Tillie-Leblond I; Malaquin F; Durieu J; Wallaert B; Tonnel AB
Clin Exp Allergy; 1997 Apr; 27(4):379-88. PubMed ID: 9146930
[TBL] [Abstract][Full Text] [Related]
8. Comparison of nasal immunohistology in patients with seasonal rhinoconjunctivitis treated with topical steroids or specific allergen immunotherapy.
Rak S; Heinrich C; Scheynius A
Allergy; 2005 May; 60(5):643-9. PubMed ID: 15813810
[TBL] [Abstract][Full Text] [Related]
9. Nasal challenges with recombinant derivatives of the major birch pollen allergen Bet v 1 induce fewer symptoms and lower mediator release than rBet v 1 wild-type in patients with allergic rhinitis.
van Hage-Hamsten M; Johansson E; Roquet A; Peterson C; Andersson M; Greiff L; Vrtala S; Valenta R; Grönneberg R
Clin Exp Allergy; 2002 Oct; 32(10):1448-53. PubMed ID: 12372124
[TBL] [Abstract][Full Text] [Related]
10. Effect of seasonal allergen exposure on mucosal IL-16 and CD4+ cells in patients with allergic rhinitis.
Pullerits T; Lindén A; Malmhäll C; Lötvall J
Allergy; 2001 Sep; 56(9):871-7. PubMed ID: 11551252
[TBL] [Abstract][Full Text] [Related]
11. Experimental and seasonal exposure to birch pollen in allergic rhinitis and allergic asthma with regard to the inflammatory response.
Kämpe M; Janson C; Stålenheim G; Stolt I; Carlson M
Clin Respir J; 2010 Jan; 4(1):37-44. PubMed ID: 20298416
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis.
Pauli G; Larsen TH; Rak S; Horak F; Pastorello E; Valenta R; Purohit A; Arvidsson M; Kavina A; Schroeder JW; Mothes N; Spitzauer S; Montagut A; Galvain S; Melac M; André C; Poulsen LK; Malling HJ
J Allergy Clin Immunol; 2008 Nov; 122(5):951-60. PubMed ID: 19000581
[TBL] [Abstract][Full Text] [Related]
13. Effect of anti-immunoglobulin E on nasal inflammation in patients with seasonal allergic rhinoconjunctivitis.
Bez C; Schubert R; Kopp M; Ersfeld Y; Rosewich M; Kuehr J; Kamin W; Berg AV; Wahu U; Zielen S
Clin Exp Allergy; 2004 Jul; 34(7):1079-85. PubMed ID: 15248853
[TBL] [Abstract][Full Text] [Related]
14. Effects of fexofenadine on inflammatory mediators in nasal lavage fluid in intermittent allergic rhinitis.
Schäper C; Gustavus B; Koch B; Ewert R; Hanf G; Kunkel G; Noga O; Gläser S
J Investig Allergol Clin Immunol; 2009; 19(6):459-64. PubMed ID: 20128420
[TBL] [Abstract][Full Text] [Related]
15. Birch pollen immunotherapy leads to differential induction of regulatory T cells and delayed helper T cell immune deviation.
Möbs C; Slotosch C; Löffler H; Jakob T; Hertl M; Pfützner W
J Immunol; 2010 Feb; 184(4):2194-203. PubMed ID: 20048125
[TBL] [Abstract][Full Text] [Related]
16. Seasonal idiopathic rhinitis with local inflammatory response and specific IgE in absence of systemic response.
Rondón C; Doña I; López S; Campo P; Romero JJ; Torres MJ; Mayorga C; Blanca M
Allergy; 2008 Oct; 63(10):1352-8. PubMed ID: 18782115
[TBL] [Abstract][Full Text] [Related]
17. Oral exposure to Mal d 1 affects the immune response in patients with birch pollen allergy.
Geroldinger-Simic M; Kinaciyan T; Nagl B; Baumgartner-Durchschlag U; Huber H; Ebner C; Lidholm J; Bartel D; Vieths S; Jahn-Schmid B; Bohle B
J Allergy Clin Immunol; 2013 Jan; 131(1):94-102. PubMed ID: 22921871
[TBL] [Abstract][Full Text] [Related]
18. Steroid-sensitive indices of airway inflammation in children with seasonal allergic rhinitis.
Meyer P; Andersson M; Persson CG; Greiff L
Pediatr Allergy Immunol; 2003 Feb; 14(1):60-5. PubMed ID: 12603713
[TBL] [Abstract][Full Text] [Related]
19. Desloratadine reduces allergen challenge-induced mucinous secretion and plasma exudation in allergic rhinitis.
Greiff L; Persson CG; Andersson M
Ann Allergy Asthma Immunol; 2002 Oct; 89(4):413-8. PubMed ID: 12392387
[TBL] [Abstract][Full Text] [Related]
20. Molecular composition and biological activity of commercial birch pollen allergen extracts.
Focke M; Marth K; Valenta R
Eur J Clin Invest; 2009 May; 39(5):429-36. PubMed ID: 19302561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
